15 Best Cheap Stocks to Buy for 2025

9. Pfizer Inc. (NYSE:PFE)

Forward P/E Ratio as of January 15: 8.98

Number of Hedge Fund Investors: 80

Pfizer Inc. (NYSE:PFE) is a leading global biopharmaceutical company committed to discovering, developing, and delivering innovative medicines and vaccines that improve patients’ lives. The company has established itself as a pioneer in the healthcare industry, addressing a wide range of therapeutic areas including oncology, vaccines, inflammation and immunology, internal medicine, and rare diseases.

Pfizer Inc. (NYSE:PFE) is placing a strong emphasis on enhancing its R&D productivity and pipeline development to drive future growth. In 2024, the company achieved significant milestones across its five strategic priorities, including oncology, commercial execution, cost reduction, pipeline advancement, and shareholder-friendly capital allocation. For 2025, Pfizer Inc. (NYSE:PFE) is focusing on improving R&D productivity and efficiency, with a goal to develop and bring to market innovative medicines and vaccines that address unmet medical needs. This includes the initiation of 13 Phase 3 studies and critical readouts for eight of them, with a particular focus on oncology, vaccines, and metabolic diseases. Key pipeline assets include the CDK4 inhibitor, the SV and PD-L1 ADCs, and the next-generation Prevnar vaccine, all of which have the potential to be blockbuster products.

Pfizer Inc. (NYSE:PFE) is also focusing on expanding its margins through continuous cost reduction and process simplification. In 2024, the company announced a $4 billion cost reduction and an additional $1.5 billion in margin improvements, driven by the implementation of advanced technologies, including AI applications that reduce G&A costs and improve manufacturing yields. These efforts are expected to enhance operational efficiency and drive profitability.